SLC5A2 and chronic kidney disease: Beyond the TGF effects, whole genome RNA sequencing followed by qRT-PCR of differently expressed genes in the kidneys suggest that empagliflozin limits complement cascade-mediated renal tissue damage in nondiabetic CKD by downregulating the expression of complement components C1QA and C1QC thus contributing to the SGLT2 blocker related amelioration of CKD progression.